Company Overview of DGI Resolution, Inc.
DGI Resolution, Inc., a human genetics company, discovers genetic risk factors for diseases ranging from cardiovascular disease to cancer. The company generates and analyzes genetic and medical data of various diseases. DGI Resolution, Inc.was formerly known as deCODE genetics Inc. and changed its name to DGI Resolution, Inc. in January 2010. The company was founded in 1996 and is based in Delaware. As of December 10, 2012, DGI Resolution, Inc. operates as a subsidiary of Amgen Inc.
Founded in 1996
Key Executives for DGI Resolution, Inc.
Vice President of Statistics
Vice President of Research
Compensation as of Fiscal Year 2014.
DGI Resolution, Inc. Key Developments
GENALICE and deCODE Genetics Enter into a Partnership for Population Wide Genomic Analysis
Jul 24 14
GENALICE announced that it is partnering with deCODE Genetics to facilitate the large-scale testing of its unique DNA data processing software solution, GENALICE MAP. After a first successful round of evaluating GENALICE MAP on speed and quality, both parties agreed to extend the evaluation to include up to 10,000 full human genomes. Population wide analysis is crucial if the potential of whole genome sequencing for medical application in patients with complex diseases is to be realized. Data processing at that level represents a major challenge, however, GENALICEs unique ability to process a full human genome on general purpose hardware in a matter of minutes makes population wide sequence variation analysis a reality. deCODE Genetics has one of the worlds larger Biobanks and is generating large amounts of full human genome data with its Illumina HiSeq X Ten Next-Generation Sequencing (NGS) machines. GENALICE will install an XL version of its all-in-one bioinformatics appliance, GENALICE VAULT, which is preloaded with MAP, and can process one full human genome every other minute.
Nextcode Gets License from Decode Genetics
Nov 3 13
Nextcode Health announced that it has secured a license for sequence-based clinical diagnostic applications using technology developed by Decode genetics. Nextcode will hold a five-year exclusive license to use the genomics platform developed by Decode genetics, including IT infrastructure and data analysis capabilities, for sequence-based clinical diagnostic applications. Nextcode will leverage Decode's Genomic Ordered Relational database infrastructure and sequence analysis systems, and will continue to develop these systems for specific needs associated with clinical research and care. Analysis will be supported by access to Decode's collection of genetic variants paired with clinical data. This technology solution will enable Nextcode's customers to analyze genomics data without investing in a substantial IT infrastructure.
NextCODE Health Secures an Exclusive License for Sequence-Based Clinical Diagnostic Applications Using Technology Developed by deCODE Genetics
Oct 23 13
NextCODE Health announced that it has secured an exclusive license for sequence-based clinical diagnostic applications using technology developed by deCODE genetics. NextCODE will hold a five-year exclusive license to use the genomics platform developed by deCODE genetics - including IT infrastructure and data analysis capabilities - for sequence-based clinical diagnostic applications. NextCODE will leverage deCODE's Genomic Ordered Relational (GOR) database infrastructure and sequence analysis systems, and will continue to develop these systems for specific needs associated with clinical research and care. Analysis will be supported by access to deCODE's substantial, proprietary knowledge base that includes more than 40 million validated variants.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries